Locoregional intravascular viral therapy of cancer: Precision guidance for Paris's arrow

T. Pencavel, R. Seth, A. Hayes, A. Melcher, H. Pandha, Richard Geoffrey Vile, K. J. Harrington

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Viral therapy of cancer includes strategies such as viral transduction of tumour cells with suicide genes, using viral infection to trigger immune-mediated tumour cell death and using oncolytic viruses for their direct anti-tumour action. However, problems still remain in terms of adequate viral delivery to tumours. A role is also emerging for single-organ isolation and perfusion. Having begun with the advent of isolated limb perfusion for extremity malignancy, experimental systems have been developed for the perfusion of other organs, particularly the liver, kidneys and lungs. These are beginning to be adopted into clinical treatment pathways. The combination of these two modalities is potentially significant. Locoregional perfusion increases the exposure of tumour cells to viral agents. In addition, the avoidance of systemic elimination through the immune and reticulo-endothelial systems should provide a mechanism for increased transduction/infection of target cells. The translation of laboratory research to clinical practice would occur within the context of perfusion programmes, which are already established in the clinic. Many of these programmes include the use of vasoactive cytokines such as tumour necrosis factor-α, which may have an effect on viral uptake. Evidence of activation of specific anti-tumour immunological responses by intratumoural and other existing methods of viral administration raises the intriguing possibility of a locoregional therapy, with the ability to affect distant sites of disease. In this review, we examined the state of the literature in this area and summarized current findings before indicating likely areas of continuing interest.

Original languageEnglish (US)
Pages (from-to)949-960
Number of pages12
JournalGene Therapy
Volume17
Issue number8
DOIs
StatePublished - Aug 2010

Fingerprint

Paris
Perfusion
Neoplasms
Therapeutics
Extremities
Oncolytic Viruses
Aptitude
Critical Pathways
Virus Diseases
Suicide
Cell Death
Tumor Necrosis Factor-alpha
Cytokines
Kidney
Lung
Liver
Infection
Research
Genes

Keywords

  • locoregional perfusion
  • oncolysis
  • viral therapy
  • virus delivery

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Pencavel, T., Seth, R., Hayes, A., Melcher, A., Pandha, H., Vile, R. G., & Harrington, K. J. (2010). Locoregional intravascular viral therapy of cancer: Precision guidance for Paris's arrow. Gene Therapy, 17(8), 949-960. https://doi.org/10.1038/gt.2010.48

Locoregional intravascular viral therapy of cancer : Precision guidance for Paris's arrow. / Pencavel, T.; Seth, R.; Hayes, A.; Melcher, A.; Pandha, H.; Vile, Richard Geoffrey; Harrington, K. J.

In: Gene Therapy, Vol. 17, No. 8, 08.2010, p. 949-960.

Research output: Contribution to journalArticle

Pencavel, T, Seth, R, Hayes, A, Melcher, A, Pandha, H, Vile, RG & Harrington, KJ 2010, 'Locoregional intravascular viral therapy of cancer: Precision guidance for Paris's arrow', Gene Therapy, vol. 17, no. 8, pp. 949-960. https://doi.org/10.1038/gt.2010.48
Pencavel, T. ; Seth, R. ; Hayes, A. ; Melcher, A. ; Pandha, H. ; Vile, Richard Geoffrey ; Harrington, K. J. / Locoregional intravascular viral therapy of cancer : Precision guidance for Paris's arrow. In: Gene Therapy. 2010 ; Vol. 17, No. 8. pp. 949-960.
@article{93e2ad6935654ca2bb81935a65e8b995,
title = "Locoregional intravascular viral therapy of cancer: Precision guidance for Paris's arrow",
abstract = "Viral therapy of cancer includes strategies such as viral transduction of tumour cells with suicide genes, using viral infection to trigger immune-mediated tumour cell death and using oncolytic viruses for their direct anti-tumour action. However, problems still remain in terms of adequate viral delivery to tumours. A role is also emerging for single-organ isolation and perfusion. Having begun with the advent of isolated limb perfusion for extremity malignancy, experimental systems have been developed for the perfusion of other organs, particularly the liver, kidneys and lungs. These are beginning to be adopted into clinical treatment pathways. The combination of these two modalities is potentially significant. Locoregional perfusion increases the exposure of tumour cells to viral agents. In addition, the avoidance of systemic elimination through the immune and reticulo-endothelial systems should provide a mechanism for increased transduction/infection of target cells. The translation of laboratory research to clinical practice would occur within the context of perfusion programmes, which are already established in the clinic. Many of these programmes include the use of vasoactive cytokines such as tumour necrosis factor-α, which may have an effect on viral uptake. Evidence of activation of specific anti-tumour immunological responses by intratumoural and other existing methods of viral administration raises the intriguing possibility of a locoregional therapy, with the ability to affect distant sites of disease. In this review, we examined the state of the literature in this area and summarized current findings before indicating likely areas of continuing interest.",
keywords = "locoregional perfusion, oncolysis, viral therapy, virus delivery",
author = "T. Pencavel and R. Seth and A. Hayes and A. Melcher and H. Pandha and Vile, {Richard Geoffrey} and Harrington, {K. J.}",
year = "2010",
month = "8",
doi = "10.1038/gt.2010.48",
language = "English (US)",
volume = "17",
pages = "949--960",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Locoregional intravascular viral therapy of cancer

T2 - Precision guidance for Paris's arrow

AU - Pencavel, T.

AU - Seth, R.

AU - Hayes, A.

AU - Melcher, A.

AU - Pandha, H.

AU - Vile, Richard Geoffrey

AU - Harrington, K. J.

PY - 2010/8

Y1 - 2010/8

N2 - Viral therapy of cancer includes strategies such as viral transduction of tumour cells with suicide genes, using viral infection to trigger immune-mediated tumour cell death and using oncolytic viruses for their direct anti-tumour action. However, problems still remain in terms of adequate viral delivery to tumours. A role is also emerging for single-organ isolation and perfusion. Having begun with the advent of isolated limb perfusion for extremity malignancy, experimental systems have been developed for the perfusion of other organs, particularly the liver, kidneys and lungs. These are beginning to be adopted into clinical treatment pathways. The combination of these two modalities is potentially significant. Locoregional perfusion increases the exposure of tumour cells to viral agents. In addition, the avoidance of systemic elimination through the immune and reticulo-endothelial systems should provide a mechanism for increased transduction/infection of target cells. The translation of laboratory research to clinical practice would occur within the context of perfusion programmes, which are already established in the clinic. Many of these programmes include the use of vasoactive cytokines such as tumour necrosis factor-α, which may have an effect on viral uptake. Evidence of activation of specific anti-tumour immunological responses by intratumoural and other existing methods of viral administration raises the intriguing possibility of a locoregional therapy, with the ability to affect distant sites of disease. In this review, we examined the state of the literature in this area and summarized current findings before indicating likely areas of continuing interest.

AB - Viral therapy of cancer includes strategies such as viral transduction of tumour cells with suicide genes, using viral infection to trigger immune-mediated tumour cell death and using oncolytic viruses for their direct anti-tumour action. However, problems still remain in terms of adequate viral delivery to tumours. A role is also emerging for single-organ isolation and perfusion. Having begun with the advent of isolated limb perfusion for extremity malignancy, experimental systems have been developed for the perfusion of other organs, particularly the liver, kidneys and lungs. These are beginning to be adopted into clinical treatment pathways. The combination of these two modalities is potentially significant. Locoregional perfusion increases the exposure of tumour cells to viral agents. In addition, the avoidance of systemic elimination through the immune and reticulo-endothelial systems should provide a mechanism for increased transduction/infection of target cells. The translation of laboratory research to clinical practice would occur within the context of perfusion programmes, which are already established in the clinic. Many of these programmes include the use of vasoactive cytokines such as tumour necrosis factor-α, which may have an effect on viral uptake. Evidence of activation of specific anti-tumour immunological responses by intratumoural and other existing methods of viral administration raises the intriguing possibility of a locoregional therapy, with the ability to affect distant sites of disease. In this review, we examined the state of the literature in this area and summarized current findings before indicating likely areas of continuing interest.

KW - locoregional perfusion

KW - oncolysis

KW - viral therapy

KW - virus delivery

UR - http://www.scopus.com/inward/record.url?scp=77955654126&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955654126&partnerID=8YFLogxK

U2 - 10.1038/gt.2010.48

DO - 10.1038/gt.2010.48

M3 - Article

C2 - 20445580

AN - SCOPUS:77955654126

VL - 17

SP - 949

EP - 960

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 8

ER -